l c interview, page-58

Perhaps a bit premature, we haven't seen what's in the presentation yet.  It's reviewed and selected, so must be a fairly solid piece of work and I doubt that includes speculation.  Besides, wasn't the cutoff for submissions early February?  The CR in the 1B might not have happened in time to make the cut, no idea what the rules are on amendments.

That said, ongoing improvement once clear of chemo would be a good sell in Q & A time.  I suspect the LT info is something they were after all along, more anticipated than the trial notes suggest.  The immune-monstering effects of chemo are well known, but they needed to work with the SOC.  Get the nuts and bolts of the trial out of the way, tick off safety plus dosage and then move onto the exciting stuff - LT further dosing with Her-vaxx in patients without chemo-compromised immune systems.  Meanwhile, they're already cracking on with the P2 and checking out the possibility of an extra trial site in India.  It seems a good use of time to me.

Cheers.